 |
 |

TB Drug Research Picks Up the Pace
Tracy Hampton, PhD
JAMA. 2005;293:2705-2707.
 |
 |
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
 |
 |
As the current standard of care for tuberculosis (TB) is based on less-than-ideal drugs that were discovered over four decades ago, TB treatment could use a shot in the arm. And indeed, renewed interest in TB drug research across the board in the nonprofit, academic, and commercial realms is funneling promising candidates into the TB drug pipeline.
"A number of years ago, there was nothing on the horizon, and now everyones energized," said Scott Franzblau, PhD, director of the Institute for Tuberculosis Research at the University of Illinois at Chicago.
By the end of this year, at least a half dozen drugs will be in clinical trials for TB, said Melvin Spigelman, MD, director of research and development at the nonprofit Global Alliance for TB Drug Development (the TB Alliance), in New York City. "I dont think anyone wouldve predicted that."
DRUGS ON THE HORIZON
|